Foghorn Therapeutics Inc (FHTX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Foghorn Therapeutics Inc stock (FHTX) is currently trading at $4.93. Foghorn Therapeutics Inc PS ratio (Price-to-Sales) is 9.50. Analyst consensus price target for FHTX is $11.44. WallStSmart rates FHTX as Sell.
- FHTX PE ratio analysis and historical PE chart
- FHTX PS ratio (Price-to-Sales) history and trend
- FHTX intrinsic value — DCF, Graham Number, EPV models
- FHTX stock price prediction 2025 2026 2027 2028 2029 2030
- FHTX fair value vs current price
- FHTX insider transactions and insider buying
- Is FHTX undervalued or overvalued?
- Foghorn Therapeutics Inc financial analysis — revenue, earnings, cash flow
- FHTX Piotroski F-Score and Altman Z-Score
- FHTX analyst price target and Smart Rating
Foghorn Therapeutics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Foghorn Therapeutics Inc (FHTX) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth, institutional own.. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Foghorn Therapeutics Inc (FHTX) Key Strengths (2)
Revenue surging 223.80% year-over-year
71.78% of shares held by major funds and institutions
Supporting Valuation Data
Foghorn Therapeutics Inc (FHTX) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Very expensive at 9.5x annual revenue
Very expensive at 10.7x book value
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Foghorn Therapeutics Inc (FHTX) Detailed Analysis Report
Overall Assessment
This company scores 25/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 2 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 1.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, Institutional Own.. Growth metrics are encouraging with Revenue Growth at 223.80%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Sales (9.50), Price/Book (10.71) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -470.40%, Operating Margin at -211.90%, Profit Margin at -240.30%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -470.40% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 223.80% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
FHTX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
FHTX's Price-to-Sales ratio of 9.50x trades at a deep discount to its historical average of 419.15x (9th percentile). The current valuation is 100% below its historical high of 2761.53x set in Dec 2020, and 82% above its historical low of 5.23x in Jan 2024.
WallStSmart Analysis Synopsis
Data-driven financial summary for Foghorn Therapeutics Inc (FHTX) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Foghorn Therapeutics Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 31M with 224% growth year-over-year. The company is currently unprofitable, posting a -240.3% profit margin.
Key Findings
Revenue growing at 224% YoY, reaching 31M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Spending 74% of revenue (23M) on R&D, reinforcing its commitment to innovation and future growth.
The company is unprofitable with a -240.3% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -22M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Foghorn Therapeutics Inc maintain 224%+ revenue growth, or will competition slow it down?
Volatility is elevated with a beta of 3.12, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Foghorn Therapeutics Inc.
Bottom Line
Foghorn Therapeutics Inc is a high-conviction growth story with revenue accelerating at 224% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -240.3% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(10 last 3 months)
| Insider | Type | Shares |
|---|---|---|
MAYNARD, RYAN D Chief Financial Officer | Buy | +400,000 |
| Insider | Type | Shares |
|---|---|---|
GOTTSCHALK, ADRIAN Director, Chief Executive Officer | Buy | +1,075,000 |
Data sourced from SEC Form 4 filings
Last updated: 8:21:43 AM
About Foghorn Therapeutics Inc(FHTX)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops drugs that target genetically determined dependencies within the chromatin regulatory system. The company is headquartered in Cambridge, Massachusetts.